Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Novo Nordisk A/S
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06717698CT.gov A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Kidney Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| nnc0519-0130 (this asset) | Novo Nordisk A/S | P2 | CCC · 53 |
| Sodium Ferric Gluconate | Watson Pharmaceuticals | P4 | BBB |
| Iron(Ii) Sulphate (1:1), Heptahydrate | Watson Pharmaceuticals | P4 | BBB |
| Semaglutide | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Clopidogrel | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Aspirin | Hospital Alemão Oswaldo Cruz | P4 | BB |
| Retatrutide | Eli Lilly and Company | P3 | BB |
| Cefadroxil Anhydrous | Mayo Clinic | P4 | BB |
| Dabigatran Etexilate | Irina Ermolaeva | P4 | BB |
+42 more in the Chronic Kidney Disease cohort
Other indications for nnc0519-0130
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P2 | CCC · 53 |
| Type 2 Diabetes Mellitus | — | P1 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. nnc0519-0130 in Chronic Kidney Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nnc0519-0130-chronic-kidney-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →